Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma And Civica Ship Eight Essential Injectables

Heparin To Be Followed By Seven Other Essential Injectable Medicines

Executive Summary

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

You may also be interested in...



Hikma’s Olafsson Sees Benefits From Broad Injectables Portfolio

Shortages are still driving growth in the US injectables market for Hikma, but the breadth of the firm’s portfolio means it has less exposure to the pressures of in-shortage products returning to market, according to CEO Siggi Olafsson.

Providers Support FDA Quest For Public Drug Manufacturing Quality Ratings

Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.

Civica Rx Gets $55m Investment

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel